Comparative Study of Detection of Epidermal Growth Factor Receptor and Cytokeratin - 19 Mrna in Peripheral Blood of Breast Cancer Patients by Reverse Transcription Polymerase Chain Reaction
李锋,任军,贾军,尤向辉,汪海丹,张燕军,郭晓彤,贠军,斯晓明
DOI: https://doi.org/10.3969/j.issn.1672-4992.2005.02.004
2005-01-01
Journal of Modern Oncology
Abstract:Objective To evaluate the feasibility of de tecting epidermal growth factor receptor (EGFR) mRNA by reverse transcription po lymerase chain reaction(RT-PCR)in peripheral blood of patients with breast cance r and to explore its significance. Methods RT-PCR assay w as applied to detect the expression of EGFR mRNA in the peripheral blood of 40 p atients with breast cancer and in 30 healthy donors. The result of EGFR mRNA was compared with that of known marker of circulating epithelial cells:CK-19. Results In peripheral blood from 30 healthy donors,none of EGF R mRNA was detected,but the positivity of CK19 mRNA expression was 26.7% (8/ 30) .In contrast ,EGFR mRNA was detected in 13 of 40(32.5%)patients with breast canc er,compared with healthy donors (P0.01),there was significant d ifference between the two groups. CK-19 mRNA was found in 14 of 40(35.0%), compa red with healthy donors (P0.05) and there was no statistical di fference. On the other hand, the expression of EGFR was observed in 25(62.5%) of tumor tissues by immunohistochemistry. We found that all patients who expressed EGFR mRNA in peripheral blood were also expressing EGFR in primary tumors. Pati ents with a high expression of EGFR in tumoral breast tissues display high expre ssion of EGFR in peripheral blood as well(P0.01). EGFR mRNA w as expressed in 5 of 26(19.2%) breast cancer patients without any treatments bef ore, but the positivity for EGFR mRNA expression was 57.1% (8/ 14) in breast can cer patients who have received treatments before. There is significant differenc e between two groups above (P0.05). Expression of EGFR mRNA was detected in 1of 6 (16.7%) metastatic breast cancer patients who have received P aclitaxel involved salvage chemotherapy, however, the positivity for EGFR mRNA e xpression was 87.5% (7/ 8) in them who have never received Paclitaxel contained salvage chemotherapy, there was significant difference between two groups ( P0.05). Conclusion CK-19 mR NA showed no dia gnostic value as marker of circulating tumor cells in breast cancers. However, E GFR mRNA in blood may be a useful marker of circulating tumor cells in breast ca ncers. Detecting EGFR mRNA in peripheral blood of patients with breast cancer us ing RT-PCR can be used as a prognostic indicator. Paclitaxel may reduce the risk of relapse and metastasis of breast cancer.